Abstract: Gold has always aroused great interest in the history of mankind. It has been used for thousands of years for jewelry, religious cult valuables, durable goods and in the art world. However, few know that such a precious and noble metal was exploited in the past by the ancients also for its therapeutic properties. More recently, in the twentieth century some complexes containing gold centers in the oxidation state +1 were studied for the treatment of the rheumatoid arthritis and the orally-administered drug Auranofin was approved by the FDA in 1985. From the chemical point of view, gold derivatives deserve special attention due to the unique position of this metal within the periodic table, which results in unconventional relativistic effects and, ultimately, in the highest electronegativity, electron affinity and redox potential among all metals. In this review, after an introduction concerning the use of gold complexes in medicine, we have examined all the patents internationally or nationally published in the years 2010 (until December 31, 2015 and describing new inorganic compounds containing gold(I) and gold(III) with proved therapeutic properties. These patents were filed to mainly protect compounds with promising anticancer and anti-inflammatory activities. In particular, this work explores both coordination compounds containing ligands with various donor atoms (e.g., N-, O-, S-and -P) and organo-gold derivatives with at least one Au-C bond. The toxicological profile and the intracellular targets reported for some among the patented gold derivatives are discussed.
INTRODUCTION

The life-driving contribution and the medicinal potentialities of inorganic chemistry
In the last century, some key discoveries have unlocked a new era for the research of inorganic compounds, ranging from paleo-biological interests to medicinal applications [1] [2] [3] [4] [5] . To date, twenty-five elements are thought to be essential for mammalian biochemistry, namely H, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, V, Mn, Fe, Co, Ni, Cu, Zn, As, Se, Mo, Sn and I [1, 6, 7] . However, the biochemistry of some elements, such as Si, V, Mn, Ni, As and Sn, is poorly understood [8] . Remarkably, essentiality is not associated only with the element itself, but with specific compounds of that element. The vitamin B12 is an example as it possesses a Co(I) ion in its core. On the other hand, at the physiological level, the xanthine oxidase enzyme, whose dysfunctions are related to gout, is another interesting metal-containing biomolecule which can oxidize xanthine to uric acid via the catalytic properties of the Mo(VI) complex in its active site [9] .
With respect to the medicinal chemistry, the first commercially-available inorganic molecule with therapeutic properties was the arsenic-based antisyphilis drug Arsphenamine (Salvarsan ® ), discovered in 1910 by Paul Ehrlich (awarded with Nobel Prize in 1908) and patented the year after [10, 11] . Salvarsan ® , and the related drug Neosalvarsan ® (Figure 1.A) , became soon the most widely prescribed drugs, remaining the most incisive cure for syphilis until penicillin became available in the 1940s. This successful story is an effective example of the Paul Ehrlich's "Magic Bullet" theory. In other words, it is possible to fight infectious diseases through a systematic search for drugs that kill invading micro-organisms without damaging the host [12] . More recently, another arsenic-containing agent, As 2 O 3 (Trisenox ® - Figure 1 .B), has been clinically exploited and it is one of the most effective drugs for the treatment of acute promyelocytic leukemia [13, 14] . Transition metal complexes, in particular those containing noble metals, have played a role of paramount importance in other medical fields, including the oncological one [15] . In fact, transition metals stand out among other elements as chemotherapeutic weapons or powerful tools in tumors, cardiologic and neurological disorders, and kidney or liver abnormalities. is the archetype of metal-based anticancer agents and is widely prescribed worldwide (alone or in combination therapy) as much as 70% of treatments against many types of malignancies, including testicular cancer, melanoma, bladder and non-small-cell-lung carcinomas and, in combination therapy, it is considerably active against ovarian neoplasm [16, 17] .
In the first scenario, cisplatin ([cis-[Pt
Concerning the use of inorganic chemistry for diagnostic purposes, many compounds containing radioactive isotopes are daily produced and immediately administered in large or medium-sized hospitals. The two main diagnostic techniques, PET (positron emission tomography) and SPECT (single photon emission computed tomography), allow to obtain several scans of the human internal tissues via the i.v. administration of a radioactive compound followed by detection of its decay products (γ rays, both for PET and SPECT).
The most common radionuclide-containing compound with applications in high resolution PET is 2-Deoxy-2- In(III) and 201 Tl(III), are widely employed [1] [2] [3] 18, 19] . Another application of inorganic compounds in medical diagnostics is provided by the Gd(III) complexes as contrast agents in magnetic resonance imaging (MRI) [20] [21] [22] .
Chrysotherapy, an old alchemical milestone reassessed and updated for the modern therapies
Among all elements, gold has always fascinated human beings, leaving a mark on cultures, arts, and also medicine. The earliest therapeutic uses of gold can be traced back to the ancient Egyptian and Chinese cultures around 3000-2500 BC [23, 24] . Following the course of history, in medieval Europe, alchemists developed a number of methods for preparing many elixirs referred to as aurum potabile, most of them containing a little quantity of colloidal gold. Later, a liquor drink, known as cordial, could be found in the pharmacopoeias of the 17 th century and consisted in a suspension of the finely-divided noble metal. Nicholas Culpeper prescribed it for the treatment of illnesses "caused by a decrease in the vital spirits, including fever, melancholy, fainting, and sickness" [25, 26] .
In addition to the medical uses of the native and the colloidal states of gold, also its coordination compounds played a key role in the development of the modern medicine. In fact, in the 19 th century, an aqueous mixture of Na[Au
III
Cl 4 ] and NaCl was used as a treatment for syphilis [26] . The term chrysotherapy (χρυσός -in Greek stands for gold) was coined for the usage of gold-based compounds in the twentieth-century medicine, and goes back to the pioneering work of the German bacteriologist Dr. Robert Koch (awarded the Nobel Prize in 1905) whose discovery in 1890 was associated with the bacteriostatic activity of gold(I) cyanide K[Au I (CN) 2 ] against the tubercle bacilli. Gold therapy for tuberculosis was subsequently introduced in the 1920s. The suggestion that the tubercle bacillus was also one of the causes of the rheumatoid arthritis led to the use of gold compounds as therapeutic agents for this disease [27] . It should be highlighted that gold-based treatments proved soon to be ineffective for tuberculosis. In contrast, after a thirty-year debate, a clinical study confirmed the effectiveness of chrysotherapy against rheumatoid arthritis. In fact, Auranofin (2,3,4,6-tetraacetyl-β-1-D-thioglucopyranosato-S-(triethylphosphine)gold(I)) (Figure 2.A) is nowadays the most effective metal-based treatment against this autoimmune disease and its use is normally recommended when it is necessary to relieve symptoms in adult rheumatoid arthritis poorly controlled with other therapies [28, 29] .
Auranofin (Ridaura ®
, approved for clinical use by oral administration, is a monomeric species with a linear coordination geometry, able to cross the cell membrane due to the lipophilic phosphine ligand. Its mechanism of action in vivo is still unknown, but is certainly associated with the rapid displacement of the tetra-acetylthioglucose ligand by ligand-exchange reactions on the Au(I) ion [30] . On the contrary, the phosphine is removed more slowly by similar processes after about 24 hours, causing fewer toxic sideeffects compared to the forerunner polymeric agents, such as the aurothioglucose (Solganal To date, chrysotherapy is clinically addressed not only to inflammatory diseases. In fact, Auranofin is nowadays used, alone or in combination therapy, also for cancer treatment in clinical trials (phase I and II for leukemia, ovarian and lung cancers) [31, 32] . Additional effects have been recently reported in terms of inhibition of various thiol-containing enzymes, antimicrobial and antifungal activity [33, 34] .
In the mid-1980s the first reports of the anticancer activity of gold compounds appeared. In this regard, two rationales have been taken into account for the investigation of gold compounds as antineoplastic agents: i) similarities between gold(III) square-planar complexes and their platinum(II) analogues (their archetype cisplatin approved in 1978 by FDA as antineoplastic drug) and ii) the possibility to synthesize gold(I) and gold(III) complexes functionalized with organic drugs and/or solubilizing agents as ligands, in order to modulate or confer new properties on the metal ion. However, the generally reducing physiological environment allows gold(III) compounds to be reduced in vivo to gold(I) species and, in turn, to metallic gold atoms. Consequently, a proper selection of the ligands is required to enhance the stabilization of the metal center in its oxidation state, by lowering its reduction potential [35] . Auranofin proved cytotoxic towards tumor cells in vitro, and this led to the identification of other Au(I) phosphines with a broader spectrum of antitumor activity, in particular the bis-chelated Au(I) diphosphine complexes (of the type [Au I (DPPE) 2 ]Cl; DPPE = bis (diphenylphosphino)ethane, Figure 2D ). They were selected as interesting candidates for therapeutic uses and firstly patented by Berners-Price and co-workers in 1986 [36] [37] [38] . In addition, some Au(III) complexes with a bidentate ligand, such as [Au Figure 2E ) and its acetate analogue first reported by Fricker in 1996, showed interesting biological properties [39, 40] . These foremost attempts suggested that a higher stability and, hence, an enhanced delivery of gold along with lower toxicity could be obtained with less labile chelating ligands with N-, S-and Pdonor atoms. From the chemical point of view, the compounds reported by Berners-Price and Fricker are stabilized against gold reduction under physiological conditions by the di-phosphino ligands [37, 41, 42] .
In last decades, various classes of gold compounds were synthetized and tested from the biological point of view in different laboratories worldwide, exhibiting outstanding therapeutic effects. In addition to chlorides and bromides, these complexes involve N-, O-, P-and S-donor coordinating ligands [37, 43] . In this context, some gold(III) complexes with chelating S-donor dithiocarbamato ligands (including aminoacids) showed a very promising anticancer activity against various tumor models associated with a good toxicological profile and were nationally patented in 2004 [44] . Lately, many organometallic complexes with a pure σ-coordination have been synthesized as well (conversely, the π-Au-C bond counterparts are unstable under most conditions [45] ), and have showed interesting biological properties. Among all these compounds, some classes have been protected by patents (either national or international) and the newest ones, whose publication occurred from 2010 to December 31, 2015 will be discussed in detail in the next sections.
Why gold is so fascinating from the chemical point of view?
Unlike the silvery color of other transition metals (except copper), gold ( 8 ), even if some complexes with the metal ion in the -1, +2, +4 and +5 oxidation states are reported in literature [46] . The solution chemistry of the gold(I) and gold(III) ions is various and, in some ways, quite intriguing. Gold(I) can form linear, trigonal-planar or tetrahedral diamagnetic complexes (geometrical examples are reported in Figure 3 .A, B and C, respectively). Regarding its chemistry in solution, it is considered a very soft metal center by Pearson's concept (Hard Soft Acid Base Theory), and this property is highlighted when the metal reacts with potentially bi-dentate (S-vs O-donor, N-vs Odonor) ligands. On the other hand, gold(III) is a less soft metal ion than gold(I) and, thus, it is able to form many diamagnetic complexes with hard ligands, containing oxygen and nitrogen donor atoms. However, gold(III) displays higher selectivity toward soft (e.g., sulfur-based) ligands, forming complexes with square planar geometry (see Figure  3.D) . Moreover, when speaking about post-lanthanoid elements (with atomic number>72, Au = 79), the relativistic effects have to be taken into account so to better describe their chemistry. In fact, the large number of protons in their nuclei results in a no-longer negligible relativistic effect on their electrons. In the case of gold, this phenomenon causes a stabilization of the outer 6s orbital (direct effect) and a destabilization with a spatial-expansion of the non-core 5d orbitals (indirect effect). As a consequence, since the energy gap between these two valence levels becomes smaller with respect to the other elements of the 6 th period [47] [48] [49] [50] , pure gold absorbs visible light. In particular, it strongly absorbs blue and violet and reflects red and yellow. Moreover, the relativistic effect can pave the way to understanding of the electronic properties, including the relativistic destabilization of the 5d orbitals (above referred to as indirect effect) which allows the easy formation of the oxidation state +3. Conversely, the relativistic stabilization of the 6s orbital (direct effect) accounts for the formation of the pseudohalogen auride ion, in which the metal is in the oxidation state -1. As a consequence of this behavior, gold is the most electronegative transition metal and according to the Pauling's scale it possesses a value of electronegativity of 2.4 (comparable to that of iodine, 2.66; in comparison, Cu and Ag have 1.90 and 1.93, respectively) and the value of its standard electrochemical potential (E 0 ) for each reduction is higher than that of oxygen (E [51] .
On the basis of these chemical considerations, the peculiar properties of gold have been exploited for several applications. To date, many complexes containing gold in +1 and +3 oxidation states are reported in literature mainly for catalysis and material science evelopment [52, 53] . Furthermore, a number of gold compounds has shown interesting therapeutic properties against cancer or inflammatory diseases. When exploiting the reactivity of gold derivatives at the physiological level, one should bear in mind also the metal noble character. In fact, the stabilization of the oxidation states +1 and +3 is of paramount importance to observe any kind of biological activity (in terms of ligand exchange, redox processes etc.). On the other hand, the metal center can ultimately undergo a reduction process, thus leading to the formation of an inert non-toxic species, namely Au 0 . Nevertheless, only a few among the promising compounds reported in literature have been patented as candidates for further advanced studies and, hopefully, for entering clinical trials.
PATENTS PRESENTATION
This review covers the successful results obtained with gold complexes in the biomedical field and has been laid out in two main parts on the basis of the metal oxidation state. The first section is related to recent patents involving gold(I) complexes while the second is focused on gold(III) coordination compounds. Overall, 21 patents are described, followed by two sections specific for the toxicological profile and the biological targets identified in some inventions.
Gold(I)-based derivatives: fields of application, structures and activity data
This review covers 21 patents whose 11 protect different gold(I) compounds (Table 1, records 1-11), 4 of the latter containing at least one direct gold-to-carbon bond (organometallic derivatives). From the historical point of view, the start of organogold chemistry traces back to the beginning of the 20 th century with the work of Pope and Gibson who exploited alkylic ligands [54] . Only about sixty years later the first examples of gold derivatives involving arylic ligands were reported [55, 56] . Then, this branch of chemistry widely grew, mainly in material science [57] [58] [59] . Another main field of application is the catalysis [60] wherein, with respect to the comprehensive organometallic chemistry, three Nobel Prizes in Chemistry have been awarded in the present century (2001, 2005 and 2010) . However, in the last years there was a burgeoning interest in the pharmacological field as well. As in most gold(I) compounds, the metal center in organogold(I) derivatives is usually two-coordinated in a linear coordination geometry (Figure 3) . The first four patents described below are related to gold(I) complexes with σ-bonded organic ligands and covalent Au-C bonding of low polarity. According to literature data [50, 60, 61] , gold(I) with a closed-shell 5d 10 electronic configuration is a very weak π-acceptor metal center, and bonding from π-orbitals of the ligands into the empty 6p orbitals of the metal is associated with low stability. Conversely, the here considered ligands are poor π-acceptors as well, thus preventing possible back bonding from the metal. Taken together, these considerations account for a single Au-C σ-bond for all the patented organogold complexes. The last seven patents of this class (Table 1, records 5-11) focus on gold(I) coordination compounds with N-, P-and Sdonor ligands.
In 2011 Ott and co-workers filed a patent ( Anticancer and anti-inflammatory agents.
Anticancer agents.
For clarity reasons, the letters associated to the substituent groups in the general formulae are mantained as reported in the original patents and their nature is explained in detail throughout the text.
The second ligand (A) can be either a phosphine or carbene group [62, 63] . These compounds are claimed for use as anticancer chemotherapeutics, antirheumatics, angiogenesis inhibitors or cytostatics. In this invention, the most promising compounds are alkynyl phosphine derivatives (complex I with A=PPh 3 ).
In particular, the complexes II and III ( [63] . The free alkyne ligands were tested as controls under the same experimental conditions, recording no activity in these proliferation assays.
The patent labeled as 2 in Table 1 was filed to protect gold(I) hydroxide complexes with general formula Z-Au I -OH (structure IV in Table 1 ) and dinuclear cationic derivatives of the form Z-Au I -(μOH)-Au I -Z (structure V in Table 1 ) where Z stands for two-electron donor ligands, in this case phosphines, phosphites and carbenes, including nitrogen-containing heterocyclic carbenes (NHCs) which possess unprecedented σ-donation [65] [66] [67] . It should be highlighted that NMR data and X-ray structure determination showed the two gold atoms in the dinuclear species are equivalent. Besides to be patented as catalysts for different reactions, such as skeletal arrangement of enynes, Beckman rearrangements and the Meyer-Shuster reaction, these complexes have potential in medicine as well, for example in the treatment of cancer [68] . Special focus was given on the complex VI, shown in Table 1 , where the NHC ligand is an IPr group (IPr=N,N'-bis(2,6-diisopropylphenyl) imidazol-2-ylidene) bearing two nitrogen atoms in the ring, adjacent to the carbene carbon, and this provided important stabilizing effects. Furthermore, the inventor states that the presence of alkylic substituents in the aromatic rings (steric bulk) provides additional stabilization to the carbene electron lone pair. In this invention, different methods of silver-free synthesis are reported and lead to the isolation (in the solid form) of NHC-Au-OH complexes with good yields (around 90%) [68] . The reactions can proceed in air even with technical-grade solvents reacting an alkali metal hydroxide with a gold(I) halide complex of the form Z-Au I -X, wherein Z is a two-electron donor ligand as described before and X is a halogen. Remarkably, due to its basic nature, the hydroxide group within this class of compounds can be readily replaced with a wide range of substituents often in high yield. The inventor reported also the crystal structure of compound VI, recording a distance of 2.078 and 1.935 Å for the bonds Au-O and Au-C, respectively, with a C-Au-O angle measured to be 177.1°, close to that expected for a linear complex. Interestingly, the Au-C distances found in the dinuclear derivative VII ( [69] . Despite these interesting data, this compound proved to be not selective toward cancer in vitro. In fact, the inventor compared the responses of two prostate cell lines derived from the same patient, the abovementioned P21PZ and the normal P21TZ epithelial cell line counterpart, observing similar activity for the tested compound (IC 50 = 0.35 and 0.43 μM, respectively). Similarly, the normal human urothelial cell line SV-HUC-1 showed high sensitivity to the treatment with an IC 50 value of 0.1 μM. Remarkably, the reference drug cisplatin was tested under the same experimental conditions, resulting in 20 to 100-fold higher IC 50 values than those found for the complex VI [69] .
In another invention, other organogold(I) compounds were designed, synthetized and studied from the biological point of view (Table 1 , record 3). Medicine is claimed as their scope of application as new agents to treat malignancies or infections [70] . During the investigations on the reactivity of allenoates, Hammond and co-workers unexpectedly obtained, in addition to the gold-catalyzed cyclization product coming from a defined allenoate, species of the type VIII depicted in Table 1 . For instance, the stable Au(I) γ-lactone derivatives IX and X were in situ obtained reacting the Au(I) precursor Au I (PPh 3 )Cl/AgOTf (as equivalent of Au I (PPh 3 )OTf) with the corresponding allenoates in dichloromethane at room temperature with about 70-80% yield [71] . Thus, these gold(I) derivatives are likely intermediates in the Au-catalyzed reactions of formation of carbon-carbon multiple bonds and proved stable enough to be tested in vitro for their cytotoxic activity. Their effects were evaluated against a number of tumor cell lines and two normal cell lines (sulforhodamine B assay method). In particular, the tested cell lines were H460 (human lung large cell carcinoma), M-14 (human amelanotic melanoma), DU145 (human prostate carcinoma), MCF-7 (human breast adenocarcinoma), HT-29 (human colon adenocarcinoma), K562 (human chronic myelogenous leukemia), BALB/3T3 (non-tumorigenic BALB/c mouse embryo cells), and Vero (normal cells from African green monkey kidney). The GI 50 values were reported for the two compounds IX and X (Table 1) , ranging from about 2 to 11 μM after 48-incubation (vehicle: DMSO) while the reference drug 5-fluorouracile showed higher values (3÷40 μM). These stable γ-lactone gold(I) complexes turned out to be not selective towards cancer cells as comparable antiproliferative data were obtained for the healthy cell lines BALB/3T3 and Vero. Compound IX was further tested at the National Cancer Institute of USA against a panel of 60 tumor cell lines at the single concentration of 10 μM.
The patent publication n. 4 (Table 1 , record 4) discloses a novel class of organogold complexes for use in treating cancer [72] . In particular, their general formula (labelled as XI) shows a gold(I) center with two distinct ligands. The ligand referred to as L denotes a phosphine or a Nheterocyclic carbene (NHC), while the second one is a Ndonor ligand with two substituents. The substituent A may be SO 2 or CO, instead R points out hydrogen, alkyl, haloalkyl or optionally substituted hetero-aryl groups. On the other hand, G can be chosen among hydrogen, alkyl, cycloalkyl, hetero-aryl or a group deriving from an α-or β-amino acid, or alternatively it may be another A-R group. It should be highlighted that, when aminoacids are present, the general formula gives rise to two chiral compounds with the L-amino acid and the D-counterpart, respectively. In this invention, Hoffmann and co-workers address their attention mainly to the two derivatives, XII and XIII (Table 1) , containing the aromatic amino acid tyrosine or tryptophan. These complexes involve a triflic amide motif, obtained after esterification of the corresponding amino acids to their α-amino esters, followed by the triflation of the primary amine with the corresponding anhydride. These compounds possess also a triphenylphosphine, defined as ligand L in the general formula. In comparison to the two previously-discussed patents, their approach in using widely available amino acids, instead of organo-precursors, offers two advantages over C-donor ligands. First, contrary to, for example, NHCs ligands (strong σ-donor species), the Au-N bond may undergo ligand exchange; second, the considered synthetic approach can generate with high efficiency a large number of different structures usable in future drug development and orthogonal therapeutic strategies on multiple targets [73] .
Both gold(I) derivatives (XII and XIII) were tested for antiproliferative effects in vitro (44-h treatment, vehicle: DMSO at ca. 0.1% v/v) against the human breast cancer cell lines MDA-MB-231 and MDA-MB-468, as well as against CV-1 from normal African green monkey kidney epithelial cells (control). With respect to the tumor models, the collected IC 50 values occur in the low micromolar ranges (MDA-MB-231: 5.8 ± 0.4 and 4.2 ± 0.8 μM for the compounds XII and XIII, respectively; MDA-MB-468: 0.9 ± 0.3 and 0.8 ± 0.6 μM for the compounds XII and XIII, respectively). It should be noted that the MDA-MB-468 cell line proved more sensitive to the gold(I) compounds compared to the MDA-MB-231. Furthermore, both anticancer agents displayed comparable activity to Auranofin (reference drug) in the inhibition of the MDA-MB-231 cell line. Remarkably, the ligands alone induced no significant antiproliferative affect, thus featuring that the metal center plays a critical role in the cytotoxic activity [72, 73] . Concerning the normal CV-1 cells, both compounds recorded higher IC 50 values (ca. 13 μM) compared to the malignant counterparts showing a certain degree of selectivity in vitro towards the cancer cells. Similarly, the complex Ph 3 PAu I NTf 2 (see structure XI with G=A-R= SO 2 CF 3 and L= PPh 3 ) displayed greater antiproliferative effects on the two breast tumor cell lines compared to CV-1 one, thus pointing out that a gold-triflic amide linkage can successfully trigger cancer cell death. The inventors studied also the effects coming from the pretreatment of CV-1 cells with the K + /H + ionophore nigericin (30 minutes), followed by the incubation with the compounds XII and XIII. In fact, they started from the hypothesis that the mitochondrial hyperpolarization of some adenocarcinomas, including those taken into account in this patent, is the cause of the selective inhibition of cell proliferation via an enhanced accumulation of gold(I) in the mitochondria [74, 75] . Nigericin treatment alone causes a concentration-dependent decrease in cell viability. After pretreatment, the CV-1 cells seemed more sensitized to gold(I) compounds. In contrast, despite MDA-MB-231 cells also showed a kind of sensitivity to nigericin alone, the addition of the two gold(I) compounds caused no further decrease in cell viability. It appears evident that for these gold(I) compounds the antiproliferative mechanism does not involve the mitochondrial hyperpolarization.
A series of gold(I) complexes involving triphenylphosphine (PPh 3 ) and one N-donor ligand derived from deprotonated benzyl-substituted derivatives of 6-benzylaminopurine (with general structure labeled as XIV in Table 1 ) were recently patented by Trávníĉek and coworkers in Czech (Table 1 , record 5) for their remarkable anti-inflammatory properties [76] . These coordination compounds are easily obtained as white powder products by the reaction of [Au I Cl(PPh 3 )] and the corresponding ligand (HL n ) in acetone, in the presence of aqueous NaOH. The most promising compound showing the best in vitro [77] and in vivo antiphlogistic activity [76] is a derivative of the structure XIV and possesses R 1 = F and R 2 =R 3 = H. Concerning the in vitro studies, it should be noted that the inflammatory diseases are associated with the expression of many genes, that start, sustain, and may stop their progression. Furthermore, throughout the inflammation process the cooperation of specific types of immune cells is driven by the cytokines. In this context, this class of compounds exhibited a strong ability to decrease the production of the pro-inflammatory cytokines TNF-α (tumor necrosis factor-α), IL-1β (interleukin-1β), and HMGB1 (high-mobility group protein B1) without affecting the secretion of the anti-inflammatory cytokine IL-1RA (interleukin-1 receptor antagonist) in lipopolysacharide-(LPS)-activated macrophages derived from the human acute monocytic leukemia (THP-1) cell line. In particular, in this investigation macrophages were pretreated with various complexes including XIV (R 1 = F; R 2 =R 3 = H) (at 600 nM), the drug Auranofin (100 nM) and the steroid antiinflammatory drug prednisone (1 μM), or the vehicle (DMSO) only. After 1 h, the inflammatory response was induced by incubation with LPS for various hours (except for the control cells). In particular, gene expression was measured 2, 4, and 8 h after LPS treatment, and secretion was evaluated on the cell medium 24 h after LPS addition [77] . The complex XIV (R 1 = F; R 2 =R 3 = H) was able to significantly decrease gene transcription of TNF-α at 2 and 4 h after the LPS treatment and to reduce the TNF-α secretion by a factor of ∼2.5 compared to control, with an effect more similar to prednisone than to Auranofin. However, under equimolar conditions of 100 nM, compound XIV (R 1 = F; R 2 =R 3 = H) and Auranofin displayed the same minimal effect on the TNF-α secretion. Similarly, complex XIV (R 1 = F; R 2 =R 3 = H) largely reduced the level of mRNA of the inflammation-related cytokine IL-1β and this well correlated with its low levels of secretion (by a factor of ∼7 compared to the vehicle). Remarkably, under equimolar conditions (100 nM), the Au(I) derivative caused a reduction of the IL-1β secretion comparable to that of Auranofin [77] . Concerning the extracellular HMGB1, which also exhibits pro-inflammatory properties, this series of coordination compounds showed little effect on its transcription after 2 or 4 h from LPS-treatment or even caused an increase after 8 hours. However, they reduced extracellular translocation of this dual-function protein, similarly to Auranofin [77] . With respect to the IL-1RA, which acts as a physiological antagonist of IL-1β, it is known that the ratio between the expression of IL-1β and IL-1RA plays a role of paramount importance in the inflammation homeostasis [78] . In fact, it should be highlighted that several inflammatory diseases, including arthritis, are characterized by either overproduction of IL-1 (IL-1β and/or IL-1α) and/or a decreased expression of IL-1RA. [78] This behavior results in high levels of the pro-inflammatory cytokine IL-1. In this study, the inventors calculated the ratio IL-1β/IL-1RA and found very low values for two compounds (at 600 nM), including XIV (R 1 = F; R 2 =R 3 = H), being comparable to the control cells (with no LPS treatment) and lower than Auranofin counterpart (at 100 nM). Notably, the cells treated with the organic drug prednisone (at 1 μM) recorded about a 10-fold higher ratio than the cells incubated with the lead compound [77, 79] .
With respect to in vivo studies, the inventors collected interesting results using the polysaccharide λ carrageenaninduced hind paw edema model on rats. In fact, the formation of edema is one of the symptoms of acute inflammation. These experiments were carried out using Wistar-SPF male rats (aged 6−8 weeks) at the same dosage of three patented compounds and Auranofin (10 mg/kg). For comparison purposes, indomethacin (5 mg/kg), considered here as a secondary standard for anti-inflammatory activity, was tested as well. The patented compounds were i.p. administered (as a fine suspension) exploiting 25% DMSO (v/v in water for injections PhEur) as a vehicle, prior to the injection of 1% Carrageenan (50 μL) into the plantar side of right hind paws of the rats. The paw volume was measured immediately after carrageenan injection and during the next 6 h by a plethysmometer. The degree of induced swelling was evaluated as the percentage of volume change of the right hind paw from the initial volume [77] . Among the investigated complexes, the compound XIV (R 1 = F; R 2 =R 3 = H) displayed the highest antiedematous activity, being also able to decrease the volume of the hind paw edema to a greater extent than Auranofin and indomethacin. These results were in agreement with the subsequent cytological and immunohistochemical analyses of animal tissues [77] .
Later, Trávníĉek and co-workers filed the same year other two similar patents written in Czech (Table 1 , records 6 and 7) involving gold(I) complexes with general formula [Au I (L n )(PPh 3 )] as therapeutic agents for treating tumors and inflammations. In particular, patent 6 is related to complexes involving as ligands a phosphine and a O-substituted derivative of 9-deazahypoxanthine (general structure XV in Table 1 ) [80] while the record n. 7 protects phosphinecontaining compounds with one N-donor ligand derived from deprotonated mono-or di-substituted hypoxanthine (structure XVI) [81] . In both cases, the complexes were prepared by mixing the acetone solutions of the appropriate hypoxanthine derivative and [Au I Cl(PPh 3 )], followed by the addition of aqueous NaOH, then leading to the isolation of white or pale yellow powders. Both patents contain only in vitro biological data.
Regarding the anti-inflammatory testing, the inventors studied first the cytotoxicity of all compounds against the THP-1 cell line (human monocytic leukemia) before using it to obtain differentiated macrophages. All complexes of patent 6 showed a strong antiproliferative activity (vehicle: DMSO, 24-h treatment) with IC 50 values in the range 0.8÷1.7 μM, comparable to Auranofin (IC 50 = 0.9 ± 0.1 μM). Remarkably, all the corresponding hypoxanthine-based ligands were not active. Likewise, in the other invention (Table 1 , record 7) the presented compounds displayed low IC 50 values (1.0÷2.2 μM) and the ligands proved inactive.
For the evaluation of in vitro antiphlogistic activity, the ability of all compounds to decrease the production of the pro-inflammatory cytokines TNF-α and IL-1β was evaluated in LPS-activated macrophage-like cells derived from the THP-1 cell line [82, 83] . Interestingly, all the tested complexes of the patent n. 6 significantly reduced the levels of both pro-inflammatory cytokines compared to the vehicle sample, with the compound XV (R 4 = Bn) recording very low values (5239 ± 815 and 253.4 ± 13.6 pg/mL, respectively), comparable to those acquired for Auranofin (5254 ± 865 and 210.5 ± 15.8 pg/mL, respectively) [80, 82] . In the patent n. 7, the studied gold(I) complexes significantly decreased the TNF-α secretion in a comparable fashion to Auranofin. In the last two patents the free ligands and the species Au I Cl and PPh 3 showed no antiphlogistic effect. The presence of the gold metal center within a tailored coordination environment proved to be crucial for the reduction of IL-1β secretion, with the compound XVI (R 5 = Bn) being among the best perfomers [81, 83] . A few selected compounds for both patents were tested for their effects on gene expression of TNF-α and IL-1β. All complexes as well as Auranofin were able to significantly reduce the transcription of these cytokines.
Concerning the antitumor activity in vitro, all compounds of patent 6 were evaluated by a MTT assay against eight human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (lung adenocarcinoma), G361 (melanoma), HeLa (cervix epithelioid carcinoma), 22Rv1 (prostate cancer), A2780 (ovarian carcinoma) and A2780R (ovarian carcinoma resistant to cisplatin), and compared with the reference drug cisplatin [82] . Remarkably, all gold(I) complexes displayed strong antiproliferative activity (vehicle: DMSO; 24-h treatment) towards the tested cancer cell lines, with IC 50 values ranging 0.6 to 22.8 μM. On the whole, the best performer was the compound XV with R 4 = isopropyl group. All the derivatives proved particularly active against the cancer models HOS, MCF7, 22Rv1, HOS and G361, recording IC 50 data (≤ about 4 μM) up to 5-fold lower than cisplatin [82] .
In similar tests, the coordination compounds protected with the patent n. 7 yielded antiproliferative effects higher or comparable to cisplatin on the MCF7 and HOS cell lines. In particular, three compounds, including the complex XVI (R 5 = Bn), turned out to be more cytotoxic than cisplatin with IC 50 data ranging from 3.7 to 11.3 μM [83] . Thus, their antiproliferative activity was further tested against A549, G-361, HeLa, 22Rv1 and A2780 and A2780R. Except for G-361, these three derivatives showed a significantly higher antitumor effect than the reference drug against the evaluated cancer cell lines, with IC 50 in the range 3 ÷ 22 μM. However, on the whole, the weakest antitumor effect was recorded on the A549 and HeLa cell lines [83] .
In 2009 the Nippon Chemical Industrial Co. Ltd. filed a patent written in Japanese (Table 1 , record 8) related to some unconventional tetra-coordinated gold(I) complexes with two identical chelating P-donor ligands linked with a quinoxaline moiety (general structure XVII in Table 1 ) [84] . The most interesting compound was the bis(2,3-bis(tertbutylmethylphophino)quinoxaline) gold(l) chloride (labelled as XVIII), which showed good antiproliferative effects in vitro. In particular, different molar ratios of the racemic isomer and meso isomer (i.e., 52:48, 54:46 and 44:56) were tested against the KB (oral squamous cell carcinoma) and the A375 (malignant melanoma) human tumor cell lines, obtaining in all cases IC 50 values of about 1 μM (vehicle: DMSO, 48-h incubation), lower than those of the drugs cisplatin and Taxol [84] . Recently, the same compound was also investigated towards the human promyelocytic leukemia cells HL-60, resulting in a GI 50 value of 0.87 ± 0.07 μM (racemic mixture, 24-h treatment). In addition, its antiproliferative activity was tested on a wide panel of human tumor cell lines, exhibiting broad activity (mainly on colon-and ovary-associated malignancies), except against cancer cell lines derived from stomach and the central nervous system [85] .
The Shanghai Institute of Pharmaceutical Industry filed two patents involving the same complex XVIII or very similar compounds to those of patent 8 ( Table 1 , records 9-10 -filed in 2010 e written in Chinese) [86, 87] . In particular, the first protects a pharmaceutical orallyadministered solid formulation of the previously-described chemotherapeutic (record 9) whereas the second one is related to compounds with the same general structure but with cyclic aliphatic groups as substituents R 1 and R 2 (record 10). Subsequently, some of the inventors of patents 9 and 10 reported the bis-chelated gold(I)−diphosphine compound XVIII to strongly inhibit the growth in vitro of twenty cancer cell lines (in most cases with IC 50 values < 1 μM after 48-h incubation; vehicle not stated), including cisplatin-resistant cancer cells. It is worth highlighting that the corresponding phosphinoquinoxaline ligand had no effect on some selected cancer models. Notably, the gold(I)-based compound proved to be also selective toward neoplastic cells, preserving normal mouse embryonic fibroblast cells (MEF). Furthermore, it significantly reduced the tumor growth of various xenografts in mouse models, for instance recording an inhibition of 43.8%, 72.4% and 80.5% (in terms of tumor volume, after nine days from the last treatment) at the doses of 2, 4 and 8 mg/kg, respectively (daily i.v. treatment for seven days) for the A549 cancer-bearing animals. It should be underlined that the body weight of all animals in the study never decreased. Similar results were observed in other xenografts, including murine Lewis lung cancer, human LS174T colon carcinoma and murine hepatocellular carcinoma H22 [88] .
After the description of patented gold(I) complexes of metalorganic nature, followed by heteroleptic derivatives with P-and N-donor ligands and homoleptic ones with Pdonor ligands, the last patent in this category to be considered was filed by Chi-Ming Che (Table 1, record 11) [89] . Its invention protects complexes of coinage metals in the oxidation state +1, namely copper, silver and gold, with thiourea-derived ligands for anticancer and antiinflammatory applications. In particular, the claimed general structures are cationic complexes involving N,N'-disubstituted (both cyclic and linear) thiourea ligands. The substituents can be alkyl, alkenyl, alkynil, aryl or heterocyclic groups and the counterion is referred to as a pharmaceutically acceptable anion (e.g., Cl -, Br -, I -, SO 4 2-, PF 6 -, OTf -). For cyclic ligands, a 5-to 8-membered ring is claimed. Among these derivatives (prepared with good yields, > 75%), the lead compound is XIX (Table 1) with the final stoichiometry [Au I (TU) 2 ]Cl (TU= 1,3-bis(4-methoxyphenyl)imidazoline-2-thione). The gold(I) center is coordinated by two thiourea ligands via a sulfur lone pair in a linear coordination geometry with a S-M-S bond angle and a M-S bond length of 175° and 2.236 Å, respectively. The reported complexes are stable in solid state in air and stable in DMSO (vehicle for in vitro testing, solubility up to 10 mM) for 72 hours. The complex XIX was tested against the human tumor cell lines HeLa (cervical epithelioid carcinoma), HepG2 (hepatocellular carcinoma), SUNE1 (nasopharyngeal carcinoma) and NCI-H460 (non-small cell lung carcinoma). The evaluated IC 50 values were 14.6 ± 0.7, 17 ± 1, 10.8 ± 0.2 and 3.7 ± 0.3 μM, respectively, after a 72-h treatment (DMSO at a final concentration of 1% v/v or lower). Taken together, these IC 50 values were comparable to or lower than those recorded for the benchmark drug cisplatin. Remarkably, the corresponding free ligand TU showed IC 50 values > 100 μM against all the tumor cell lines, pointing out this ligand is a non-toxic carrier of the metal center and the antiproliferative activity is triggered by gold, as planned during the design phase. Based on the lowest IC 50 value, obtained against the cell line NCI-H460, the inventor tested the compound XIX in vivo as well, on NCI-H460 xenografts in nude mice. The gold complex was i.p. administered twice-a-week (vehicle: 90% PBS, 6% polyethylene glycol 400, 3% ethanol and 1% Tween 80 v/v) at the dosage of 100 mg/kg body weight for a total of 8 times. The tumor size was reduced of 38% ± 11 (n=5) after a 28-day treatment [89] . This invention protects also heteroleptic complexes, containing a ligand L (e.g., thiolate, amine, imine, phospine, carbine, imidazole, Cl -, Br -, I -) besides one N,N'-disubstituted thiourea (cyclic or linear) ligand.
Gold(III)-based derivatives: fields of application, structures and activity data
This part of the work will focus on ten patents ( Table 2 ) that selectively bind to cell transmembrane protein aquaporins (AQPs), such as AQP1, AQP3, AQP7 and AQP9, leading to their inhibition [90] . AQPs belong to a highly conserved class of membrane channels present in all types of organisms and involved in the transport of water and small solutes such as glycerol, nitrate and urea [91, 92] . The thirteen human AQP isoforms (AQP0-12) are involved in many physiological functions [93] and are expressed in various tissues to different extents and can be classified into two groups, being either strictly selective for water (e.g., AQP1) or also permeable to small solutes including glycerol (called aquaglyceroporins) [94] . With respect to malignancies, AQPs have been reported to be up-regulated in many tumor types and to be related with enhanced risk for metastasis and poor prognosis [95] [96] [97] [98] .
To date, there are few reported AQP inhibitors with more or less interesting profiles, including inorganic salts [99] , such as AgNO 3 , HAu III Cl 4 , mercurial compounds which are not non-selective in their action and extremely toxic, and various quaternary ammonium salts [100] . In this invention, the screening of different metallodrugs for the inhibition of AQP1 (selective for water) and AQP3 (mainly specific for glycerol permeation) is reported on hRBC (human red blood cells). Special attention was given to two ionic gold(III) compounds referred to as Audien and Auphen (compounds XX and XXI in Table 2 ), wherein the metal center is stabilized by the presence of three or two nitrogen atoms on the diethylentriamine and 1,10-phenantroline ligands, respectively. Both derivatives showed anticancer properties in vitro against the human ovarian tumor cell line A2780, with IC 50 values falling in the range 3-8 μM. The complex Auphen overcame resistance to cisplatin when tested on the corresponding cisplatin-resistant cell line [101, 102] . In this patent, compounds XX and XXI proved inhibitors of glycerol transport (AQP3) in hRBC with IC 50 values of 0.78 ± 0.08 and 17 ± 2 μM, respectively, while showing only a very weak inhibitory effect on water permeability (AQP1). It is worth highlighting that no cell hemolysis was detected, thus accounting for a non-toxic inhibitory effect.
Therefore, the inventors further tested Auphen on PC12 cells (rat adrenal pheochromocytoma cells), both wild-type and stably transfected with rat AQP1 or AQP3 in order to check a possible selective effect on AQP3 glycerol transport. When treated with the gold(III) complex a drop in glycerol permeability was detected only for the PC12-AQP3 cell line, thus pointing out a selective blocking of AQP3 channel by Auphen. In this invention, the obtained results underline that the presence of hydrolysable metal-ligand bonds is required for the activity. In another patent (record 13 - [103, 104] . Their cytotoxic activity was claimed against human prostate and gastric cancer. In this context, two papers involving similar compounds with bis-chelated Ndonor ligands (DACH-DACH or DACH-ethylenediamine) were recently published [104, 105] .
{S,S-(+)-1,2-(diaminocyclohexane)}]Cl isomer (compound XXIV)
In 2011 Wang and co-workers filed two distinct patents (written in Chinese) with an Au III ClSN 2 ( [106, 107] . The first invention (patent 14) protects anticancer agents with the general structure XXV shown in Table 2 , containing a tridentate aromatic ligand (5-aryl-3-(2-pyridyl)-4,5-dihydro-pyrazole-1-thioamide) with a number of possible substituents. According to the corresponding paper [108] , a series of eight complexes was tested by the MTT assay against the human cancer cell lines HeLa and A549, recording for some of them lower IC 50 values (ca. 3-5 μM) than cisplatin against HeLa cells. The most promising complex was the one bearing the substituents R 1 = H, R 2 = 4-OCH 3 and R 3 =H, thus suggesting that changing the groups on the rings (taking into account also the position and electronic effects) may lead to distinct effects in terms of antitumor activity.
Their second patent (record 15) relates to an amide gold(III) complex with anticancer activity (complex XXVI in Table 2 ), whose production is claimed to be easy and suitable for large-scale synthesis [109] .
In another invention ( Table 2 , record 16), gold(III) complexes bearing optically active N-(2-picolinoyl)spiro [4, 4] nonane-1,6-diamine as a ligand were presented as new anticancer agents (e.g., complexes XXVII and XXVIII in Table 2 ). Despite this patent is written in Japanese, one can infer that the coordination core is of the type Au III ClN 3 [109] . Che and co-workers recently protected new gold(III) compounds as antitumor agents by means of three distinct patents. The first invention is related to both mononuclear and dinuclear species (Table 2, record 17) [110] while the second and third category of these new agents are associated only with mononuclear derivatives (Table 2 , records 18 and 19) [111] . The inventions numbered 17 and 18 involve cyclometalated N-heterocyclic carbene complexes. In the first case, the metal center is mainly bound to three carbon atoms and one N-donor atom of the ligand. Conversely, in the second class of complexes, the gold ion is usually within a coordination plane with a N 3 C stoichiometry. With respect to the Au-C bond/s, the Au(III) center may be thought dsp Similarly to the previous described organogold(I) compounds, the strong metal-carbon bonds have a pure σ-character [45] . As already mentioned, N-heterocyclic carbene (NHC) ligands have received great attention in organometallic chemistry and the ionic (both mono-and dinuclear) Au III -NHC complexes of patent n.17 contain a tridentate C-deprotonated ligand of the type R'-C^N^C-R' (wherein R'-C^N^C-R' is 2,6-diphenylpyridine or its derivative), and another 5-membered-ring NHC ligand (generally IMe, i.e. 1,3-dimethylimidazol-2-ylidene). The structure XXIX in Table 2 shows the most active compound among all the investigated complexes, endowed with very low IC 50 values (< 1 μM, 72-h treatment) against a panel of 9 human tumor cell lines (HepG2, hepatocellular carcinoma; HeLa, cervical epithelioid carcinoma; NCI-H460, non-small cell lung carcinoma; HL-60, leukemia; MDA-MB-231, breast carcinoma; B16, melanoma; SUNE1, nasopharyngeal; KB, epithelial carcinoma and its camptothecin-resistant cell line KB100). On the whole, this compound was more active (18 to 28-fold) than the reference drug cisplatin with respect to some cell lines where data were available. Furthermore, this class of compounds was selective towards cancer cells as they recorded poor cytotoxicity data on lung fibroblast cells (CCD-19Lu) [110] . The compound XXIX was also tested in vivo on nude mice bearing hepatocellular carcinoma (PLC) at 3 mg/kg/week for 28 days, resulting in a tumor growth inhibition of 47% compared to the vehicle control.
Remarkably, neither death nor weight loss or induced unwanted effects were observed during the examination period [110] .
With respect to patent n. 18, the involved complexes (general structure XXX in Table 2 ) mostly contain only one NHC ligand and a tridentate N-donor aromatic ligand. Among all the main mononuclear ionic derivatives, the compound XXXI with H2IPI (2,6-bis(imidazol-2-yl)pyridine) as a polydentate ligand, showed the best profile of anticancer activity. In particular, regarding in vitro cytotoxicity screening, six human tumor cell lines were taken into account, namely the hepatocellular carcinoma HepG2, the cervical epithelioid carcinoma HeLa, the lung carcinoma NCI-H460, the breast cancer MCF-7, the melanoma B16 and the nasopharyngeal carcinoma SUNE1. The evaluated IC 50 data were 3.3 ± 0.5, 1.4 ± 0.2, 1.4 ± 0.1, 2.9 ± 0.2, 2.2 ± 0.1 and 28.6 ±0.3 μM, respectively. Except for the SUNE1 tumor model, cisplatin showed weaker antiproliferative effects for each cell line under the same experimental conditions (72-h treatment) [111, 112] . Based on these encouraging results, the inventors tested the lead compound in vivo as well. In particular, female BALB/cAnN-nu nude mice (5-7 weeks old) bearing HeLa xenografts were treated with this lipophilic complex at 3 mg/kg or solvent control (60% polyethylene glycol 400, 30% ethanol, 10% Tween 80, then diluted with PBS) by intratumoral injection once every three days for 14 days. A growth inhibition of 76% was observed in terms of tumor et al. 116 Anticancer agents.
For clarity reasons, the letters associated to the substituent groups in the general formulae are mantained as reported in the original patents and their nature is explained in detail throughout the text. 4 3- ). In the last decade, Che and co-workers prepared a class of stable gold(III)-porphyrin derivatives but poor or no water-soluble. Therefore, the second-generation of these anticancer compounds was designed to have higher water solubility by introducing hydrophilic substituents on the porphyrin ring (general structure XXXII in Table 2 ). Furthermore, with respect to the mechanism of action, these recent complexes were designed also to block the active site of histone deacetylase. [113, 114] . The best-in-class compound contains a hydroxy-substituted porphyrin as a ligand and is prepared with yields higher than 77%. Such a complex showed outstanding anticancer activity in vitro against five types of human breast carcinoma cell lines with distinct gene expression profiles and oncogenic phenotypes. In particular, after a 24-h treatment the IC 50 values 0.5 ± 0.2, 0.08 ± 0.04, 0.04 ± 0.01, 0.007 ± 0.002 and 0.02 ± 0.01 μM were collected against the cell lines BT474, MCF-7, T47D, MDA-MB-231 and SKBR3, respectively. It should be highlighted that the cisplatin IC 5O values were ca. 100-3000 times higher than the lead compound. Similarly, the cytotoxicity of this promising gold(III) complex was evaluated also towards other cell lines, namely HeLa (human cervical epithelioid carcinoma), HepG2 (hepatocellular carcinoma), HL60 (leukemia), SUNEl (nasopharyngeal) and B16 (melanoma), collecting the IC 50 values 0.08 ± 0.01, 0.21 ± 0.03, 0.11 ± 0.02, 0.31 ± 0.09 and 0.22 ± 0.05 μM, respectively. [113, 114] . In addition, its possible cancer cell-selectivity was tested by treating noncancerous fibroblast cells, ultimately recording a ~10-600-fold lower potency, with an IC 5O value of 4.2 ± 1.7 μM. The anti-tumor effects of the lead complex were evaluated in vivo as well. Highly metastasizing MDA-MB-231 human breast cancer cells were implanted into the third-right thoracic mammary fat pad of female athymic nude mice. The animals were treated bi-weekly at three drug dosages (1.5, 3.0 and 6.0 mg/kg), i.p. administered. Although the animals well tolerated the treatment, no complete tumor suppression was found, rather a dose-dependent tumor growth inhibition over a 5-week treatment. On the contrary, the intraductal injection of only two doses at 15 mg/kg on days 7 and 11 after tumor cell injection (day 0), resulted in a complete tumor remission in 50% of the treated animals after 2 weeks from day 0. Most mice kept a tumor-free status until day 25, after which tumor relapse was observed. Remarkably, intraductal administration of cisplatin at the same dosage was associated with smaller antitumor effects and about 40% of cisplatin-treated animals died after two injections (on day 7 and 11 from initial implantation). After 5 weeks from day 0(in other words after 4 weeks without treatments), the tumor weights were evaluated post-mortem, being decreased by 73% and 34% when compared to control group for the mice treated with the gold(III) lead compound and cisplatin, respectively. [113, 114] . The used vehicle (PET) was PEG 400 (60% v/v), ethanol (30% v/v) and Tween 80 (10% v/v). This mixture was further diluted with PBS (1:9) before administration. The body weights of all treated animals (with either cisplatin or the gold(III) derivative) were slightly lower than the PET control group.
In another class of patented compounds (Table 2 , record 20), the involved ligands are chelating tetradentate N-donor dianions of the type N 2 N' 2 , leading to the formation of monocationic gold(III)-based species [115] . Their synthesis is a simple one-pot reaction and the products require minimal purification. According to the general formula XXXIII displayed in Table 2 , this invention concerns a series of gold(III) bis(pyrrolide-imine) and bis(imidazolato-imine) Schiff base complexes with different degrees of lipophilicity and steric hindrance. The complexes are claimed for use as anticancer chemotherapeutics and were designed to be planar enough to allow intercalation between DNA base pairs. Moreover, the overall charge of these lipophilic cations favors possible electrostatic interactions with the negatively charged phosphate backbone of the DNA double helix. The gold(III) chelates of this invention were screened by the National Cancer Institute (USA) against a panel of 60 different human cancer cell lines, pointing out some structure/activity relationships between different polydentate ligand-containing derivatives. Among the most promising compounds, the one labelled as XXXIV (Table 2) displayed very good activity, particularly against leukemia, breast, and colon cancer cell lines (mean GI 50 =7 μM; mean IC 50 =20 μM). Such in vitro testing showed this lead compound was more effective than cisplatin against ca. 25% of the 60 human cancer cell lines. Then, the in vivo activity was investigated on 3LL tumor model (solid Lewis murine lung carcinoma) in black mice over a 20-day period using 20 μmol/kg and 26 μmol/kg of the gold complex (administered twice/week) and cisplatin (once/week), respectively. The tumor growth inhibition was of 33% versus the 76% of the reference drug. Remarkably, the inventors chose this lung cell line, despite a poor performance of the compound in vitro, in order to evaluate a lower limit of its in vivo activity [115] .
The last invention ( Table 2 , record 21) taken into account in this review claims the preparation method and the use of Au(III)-dithiocarbamato (dtc) derivatives of oligopeptides for the treatment of tumor pathologies [116] . One of the goals of this invention is to provide Au(III) complexes characterized by satisfying antitumor properties and lack of toxicity, in particular nephrotoxicity which represents a major drawback in platinum-based chemotherapy. Moreover, an improved intracellular drug transfer is achieved by the functionalization of the metal center with oligopeptides. Another aim is to provide Au(III) derivatives easily obtainable and stable enough to make their synthetic process exploitable on a large scale at the industrial level. The investigated compounds are Au(III)-dithiocarbamato derivatives of oligopeptides with the stoichiometry [Au III X 2 (pdtc)], wherein X = halogen or pseudo-halogen and pdtc = peptide/esterified peptidedithiocarbamato and their general formula is reported as XXXV in Table 2 . To achieve improved selective drug delivery and intracellular transfer, this invention exploits specific transporter proteins named PEPT1 and PEPT2 [117] . They are membrane proteins responsible for the cellular uptake of di-and tri-peptides, and peptide-like drugs and are stereoselective toward peptides containing L-enantiomers of amino acids [118] . PEPT1 and PEPT2 have been identified in mammals and are present chiefly in epithelial cells of the small intestine, mammary glands, lung, choroid plexus and kidney, but are also found in other tissues. Both exhibit a similar substrate specificity but differ in structure, transport capacity, and binding affinity. A peculiar characteristic is their capability for sequence-independent transport of all possible di-and tripeptides as their substrate-binding site can accommodate a wide range of molecules of different size, hydrophobicity and charge [117, 118] . According to the structure XXXV, the patent discloses complexes with the subscript m ranging from 2 to 5 and the monodentate ligands X 1 and X 2 (equal or different) can be Cl, Br, I, CN and SCN. Their anticancer activity was tested both in vitro (vehicle: DMSO, 72-h incubation) and in vivo. In particular, the growth inhibition was evaluated in comparison with the reference drug cisplatin against the triple-negative human breast cancer (TNBC) cell line MDA-MB-231, as these cells are highly metastatic, invasive and resistant to cisplatin, recording IC 50 values in the low micromolar range. Moreover, the compounds were screened also toward the androgen-resistant prostate cancer PC3, obtaining IC 50 data as low as 1 μM, being 3-fold smaller than cisplatin. In the corresponding paper [119] , the inventors reported a series of antiproliferative assays on other human tumor cell lines including the prostate cancer DU145, the Hodgkin's lymphoma L540, the ovarian adenocarcinoma cisplatinsensitive 2008 and -resistant 2008-R, demonstrating that cell death occurs via apoptotic pathways [116, 119] . Overall, the ligands proved to be not active under the same experimental conditions. With respect to in vivo studies (vehicle: 1:1:1 v/v PBS, DMSO, Cremophore/ethanol (1:4)), two compounds, including the lead compound XXXVI shown in Table 2 , were tested against the estrogen receptor α-negative human breast cancer MDA-MB-231 xenograft model which is a tumor developing aggressively, and frequently leading to early gastrointestinal metastases [120, 121] . In this study, an inhibition of 53% was detected in tumor growth compared to control after a 27-day treatment at 1 mg/kg s.c.. Notably, some mice showed 85% inhibition and, in a few cases, tumor shrinkage after 13 days of treatment. Moreover, mice appeared healthy and very active throughout the experiment. The inventors recently published the results obtained also for a prostate cancer xenograft. Since PC3 cells are more invasive and more resistant to chemotherapy than DU145 counterpart, the PC3 cells were implanted in athymic nude mice and then the animals were treated every other day with intratumoral injections of either the medium or the vehicle containing 2 mg/kg of the lead compound, recording a 70% inhibitory effect with mice body weights monitored every other day. At the end of the experiment (19 days), no significant change was detected and no histologicallyobservable cytotoxicity involving animals' lung, liver, kidney or spleen was recorded [122] .
3.
TOXICOLOGY AND IDENTIFIED INTRACELLULAR TARGETS
Toxicological profiles of the patented gold(I,III) derivatives
All the compounds described in this review have shown very promising activities as antitumor or anti-inflammatory agents. On the other hand, the toxicological profile has to be taken into account when considering the possibility to carry out advanced preclinical studies in order to enter clinical trials. In this context, only a few patents or the corresponding papers (when available) report some toxicity data, which overall are quite encouraging and prove that new potential drugs containing transitions elements, such as gold, have not to be seen in a suspicious light due to the presence of the heavy metal.
Concerning the gold(I) compounds, only the patent n. 8 describes some toxicological studies [85, 88] . In particular, the acute toxicity of compound XVIII (Table 1) was studied in rats per os. From the experimental point of view, different molar ratios of the racemic isomer and meso isomer (i.e., 52:48, 54:46 and 44:56) were administered once, using corn oil as a vehicle, in order to evaluate the lethal dose 50% (LD 50 ) at the fourteenth day of observation, being 134.4, 97.4 and 118.7 mg/kg, respectively. Overall, this class of complexes proved less toxic than cisplatin. The chemotherapy was carried out at 2÷8 mg/kg. There are two recent papers related to the Japanese invention n. 8 and to the Chinese patent n. 9, respectively, reporting some toxicity studies on the same compound (XVIII). In the first one, mice treated with 300 mg/kg of the complex XVIII survived for at least 2 weeks [85] . In the second paper, ICR mice were used to evaluate the toxicity of this lead agent in terms of LD 50 . Such coordination compound and the reference drug cisplatin were administered intravenously in single doses (for the gold derivative, 55.0, 46.8, 39.7, 33.8, and 28.7 mg/kg; for cisplatin, 20.0, 16.0, 12.8, 10.2, and 8.2 mg/kg) with saline vehicle as a control (it should be underlined that the dosage used in the chemotherapy model, usually 3 mg/kg was lower than those used in toxicity evaluation) [88] . The mortality, the changes in the behavior and the physical appearance were monitored for 14 days after administration. It is worth highlighting that each dosage of the compounds was administered to 10 male and 10 female mice, resulting in a LD 50 of 42 ± 2 mg/kg and 41 ± 2 mg/kg, respectively. These values were much higher than cisplatin counterparts, namely LD 50 = 12 ± 2 mg/kg and LD 50 = 11 ± 2 mg/kg for males and females, respectively [88] . In the same paper but in separate experiments, SpragueDawley rats were injected daily with either compound XVIII at the doses of 2, 4, and 8 mg/kg or cisplatin at 1 and 2 mg/kg for 28 days, and the mortalities were recorded with the goal of measuring the long-term toxicity. Remarkably, no rat died in the gold-treated groups with a little loss of body weight. On the contrary, at the daily dosage of 1 mg/kg for cisplatin, eight out of ten rats died in 28 days (survival rate = 20%) while all rats treated with 2 mg/kg cisplatin died within 7−10 days. As several anticancer agents cause hematologic toxicity, levels of red and white blood cells in the peripheral blood of the rats were examined at the doses of 2 and 8 mg/kg for 28 days, observing no statistically significant change at the end of the injections with the gold(I) derivative [88] .
With respect to the gold(III) potential drugs, some data are available only for the patents n. 18, 20 and 21 [110, 111, 35] . Concerning the first one, in preliminary experiments two dosages of the compound XXXI (Table 2) were evaluated in mice, namely 7 mg/kg and 20 mg/kg (the dosage used in the chemotherapy model was 3 mg/kg), resulting in a slight decrease in body weight for the first concentration and a not-defined degree of toxicity for the second dose. Concerning the toxicological profile of the most promising non-macrocyclic Au(III) complex of the patent 20 (XXXIV ,  Table 2 ), the inventors collected a set of survival data for five groups of four mice each, receiving dosages from 1 to 30 μmol/kg of compound. A single dose of the tested complex was administered in the first week to each mouse followed by two injections per week for overall 50 days. Remarkably, all mice kept healthy and showed no important weight changes during the experiment. Finally, the lead compound resulted to induce chronic toxicity at dosages higher than 60 μmol/kg/week [115] . The same gold complex was selected for preliminary ADME (Administration, Distribution, Metabolism, Excretion) profiling prior to advanced pre-clinical toxicology testing. The plasma halflife (t 1/2 ) of XXXIV was < 20 min, similar to t 1/2 of the monoaquo substitution product (16 min) of cisplatin, under physiological conditions (cisplatin t 1/2 = ca. 53 min). In fact, the test gold(III) derivative was not identified in a structurally intact form by LC-MS in the protein-free fraction, thus suggesting a fast conversion of the compound into another species in the presence of plasma constituents and/or possible binding to plasma proteins. Furthermore, some transport data clearly proved that the test agent possesses the ability to freely pass across a monolayer of Caco-2 cells, taken as a model for the human small intestine mucosa. In addition, the compound was not genotoxic in vitro and, hence, better than some mutagenic clinicallyestablished drugs such as daunorubicin and its derivatives. Concerning the patent n. 21, toxicological data have been briefly described in a recent paper [35] . The main inventor reported the investigation of acute toxicity of the compound XXXVI (Table 2) under GLP (good laboratory practice) conditions in 80 mice taking into account different dosages, much higher than those used in chemotherapy (xenografts treatment at only 1-2 mg/kg). For both the considered administration routes (intravenous and oral) no clear clinical finding was observed in any of the treated animals. Likewise, no death nor signs of toxicity have been observed during the study. It should be underlined that body weight for any mouse was constant or increased during the 14-day observation period. In the course of necropsy, neither gross anatomical findings nor alterations in the main organs and tissues were detected [35] .
Intracellular targets identified for some patented gold(I,III) derivatives
The possible mechanisms of action of gold-based potential drugs have been recently reviewed in a number of papers [35, 43, 123, 124] . In the scientific community, it is widely recognized that the main target of cisplatin and its derivatives is DNA, although a very small amount of these drugs reaches the nucleus due to previous reactions with other biomolecules or due to the presence of barriers in biological fluids and/or at the cellular level. On the contrary, DNA is not the main target of gold complexes [125] . To date, the pharmacological profile of gold-based anticancer agents seems to involve different pathways resulting in modification of the cell cycle, modulation of specific kinases and other cellular processes, which eventually trigger tumor cell death. With respect to the patented complexes, the large structural variety of the used ligands and the resulting coordination geometries of the corresponding complexes lead to peculiar biological properties and, hence, a single mode of action is not conceivable for all. We describe below the intracellular targets acknowledged for the lead compounds in some patents.
Regarding the gold(I) derivatives, the inventions n. 1, 4, 8 and 11 report the inhibition of the thioredoxin reductase (TrxR). This selenoenzyme of the thioredoxin system is involved in the regulation of the redox balance, cell proliferation, apotosis and angiogenesis ( Figure 4A ) [126] . It is accepted that affecting the thioredoxin system can be associated with a drop of the mitochondrial membrane potential, followed by the release of cytochrome c, ultimately triggering the apoptotic pathway. In this regard, the patent n. 11 reports in-depth studies about the TrxR inhibition by the compound XIX (Table 1) , finding a tight-binding mode of inhibition, being basically irreversible. The enzyme activities were not recovered indeed after removal of the free inhibitors by ultrafiltration. The overall inhibitory constant was evaluated to be in the low picomolar range, showing that the complex XIX is one among the most potent TrxR inhibitors [89] . If considering cell lysates (HeLa cell line), TrxR was found inhibited after 1-h treatment with XIX, recording an IC 50 value of 50 nM. The glutathione peroxidase (GPx), another selenocysteine-containing enzyme, was taken into account and found likewise inhibited by the complex XIX but with a higher IC 50 (1 μM). On the other hand, the glutathione reductase (GR) activity was not affected by the patented complex.
The alkynyl complexes described by Ott et al. (Table 1 , record 1) displayed significant effects also as anti-angiogenic agents, affecting the blood vessel production in developing zebrafish embryos (notably, the related ligands proved to be inactive) [62] .
As concerns gold(III) derivatives, some complexes of the patent 12 were tested as possible inhibitors of aquaglyceroporins (AQP) ( Figure 4B ) [97] , finding a selective inhibition of AQP3 by the compound Auphen ( Table 2 , structure XXI) [127] . Moreover, Casini et al. demonstrated that such a derivative could act by inhibition of cyclindependent kinase (CDK) via comparative analysis with 110 standard agents with a known mechanism of action [102] .
Similarly to the aforementioned patents, Che et al. (record18) found out the inhibitory capabilities of some gold(III) complexes with NHC ligands, towards the Trx system in cell lysates [126] . On the other hand, Che and coworkers designed other compounds, protected by the patent n. 19, as histone deacetylase inhibitors. Histone deacetylases (HDAC, also referred to as lysine deacetylases) are a class of enzymes that remove acetyl groups from ε-N-acetyl lysine amino acids on histones (highly alkaline proteins), thus leading to a more tight wrapping up of the DNA duplex. HDACs are often overexpressed in malignancies and are associated with poor prognosis and survival rate [128, 129] . Thus, HDAC inhibitors (HDACi) are a new class of promising antitumor agents that can trigger apoptosis and/or induce differentiation of cancer cells, with low toxicity to healthy ones. In fact, they are able to indirectly increase the gene expression for a certain set of genes [130, 131] . In particular, the complex XXXII with R=OH is able to decrease -dose-and time-dependently -the HDAC activity in both cell cultures and isolated nuclear extracts (MDA-MB-231 human breast cancer cell line) with effects comparable or slightly lower than the know HDAC-inhibitor trichostatin A [113, 114, 132] .
In addition, the lead compound was selective towards HDAC 1, 2, 3 and 8 and able to modulate the acetylation status of histone H4 at the promoter regions of Wnt signaling molecules [113] . Quantitative PCR analysis revealed that treatment with XXXII (R=OH) significantly upregulated the mRNA levels of the Wnt-antagonist WIF1 (WNT inhibitory factor 1). Similarly, the gene transcriptions of other Wnt/β-catenin signaling molecules (e.g., WNT1, WNT5B and CTNNB1) were indirectly affected by the gold complex [113, 114] . A loss of Wnt signal-induced stabilization may account for the drop in intracellular levels of β-catenin, observed after treatment with the complex XXXII with R=OH. Notably, intracellular accumulation of β-catenin were detected in a number of human breast tumors [133, 134] and this gold complex decreases β -catenin levels in MDA-MB-231 cells as early as 4 hours after treatment [113, 114] .
The complexes of patent 20 were instead tested as poisons/inhibitors of topoisomerase I and topoisomerase II ( Figure 4C ). All compounds target topoisomerase II and some of them have shown effects also on topoisomerase I. Interestingly, the lead compound XXXIV (Table 2 ) acts as a topoisomerase II poison at low concentrations and an inhibitor of the enzyme at high concentrations [135] . Topoisomerase II is an essential nuclear enzyme found in all living cells which participates in various DNA metabolic processes, such as transcription, DNA replication, chromosome condensation, and de-condensation, and is responsible for the segregation of daughter chromatids during mitosis [136] .
The inventors of patent 21 identified the proteasome ( Figure 4D) as a major target both in vitro and in vivo [116, 121] . The proteasome is an ATP-dependent protease and plays a fundamental role in nuclear and cytoplasmic homeostasis by hydrolyzing a large number of proteins labeled with poly-ubiquitin chains. The ubiquitin-proteasome system (UPS) is involved in several intracellular processes such as cell cycle progression, apoptosis, DNA damage and repair, drug resistance, angiogenesis and cell differentiation [137] . Although these peptidomimetics closely resemble cisplatin from the structural point of view (i.e., square planar geometry with a d 8 electronic configuration), they turned out to be potent proteasome inhibitors and, in contrast with the platinum-based drugs, they seem not to reach the nuclear DNA. In addition, this class of complexes inhibited the selenoenzyme thioredoxin reductase and promoted mitochondrial swelling with the subsequent release of cytochrome c [122] .
DISCUSSION AND PROSPECTS
According to the World Health Organization, in developed countries, cancer incidence has now surpassed cardiovascular diseases, thus being the leading cause of death. Likewise, inflammatory diseases are continuously growing and represent a burden for patients, families and the whole society in terms of both human and financial costs. In spite of the huge number of organic compounds studied worldwide every year, including the libraries obtained by combinatorial technologies for high-throughput screening, only one among 5,000/10,000 derivatives that enter the pipeline, receives approval. Taking into account this kind of "death valley", new horizons have to be explored along with changing drug design and development strategies. In this regard, the periodic table of the elements offers many novel possibilities in the biomedical field. For instance, transitions elements have a large variety of oxidation states, and hence coordination numbers and geometries which can be tuned via selection of proper ligands, resulting in peculiar and biologically-relevant properties. Regarding the anticancer chemotherapy, this great deal of potential was serendipitously discovered by Barnett Rosenberg in 1969 and subsequently clinically-exploited, upon FDA approval of the metal-based drug cisplatin in 1978, to treat various solid malignancies. Afterwards, other platinum-based pharmaceuticals have been clinicallyestablished and, in the last decade, there has been a burgeoning interest in innovative antitumor drugs involving different metals, as shown by the ever-growing number of publications and citations per year. To date, except for immunotherapies (very expensive and exploitable only in a low percentage of patients), chemotherapy still leads to the occurrence of severe side toxicity. Thus, new potent selective anticancer therapies are urgently required to significantly decrease the adverse effects in normal tissues. With respect to anti-inflammatory treatments, the real forerunner is Auranofin which is at present the most effective metal-based treatment against autoimmune diseases such as the rheumatoid arthritis. In the introduction, the chemical and biological properties of this drug have been described.
It is worth highlighting that the present drug marketing is monopolized by organic molecules. From the chemical point of view, very few scientists have in mind the huge possibilities offered by inorganic compounds (both coordination and organometallic ones) in medicine. Although the distinction between inorganic and organic species is not absolute, any substance in which at least one element different from carbon, hydrogen, oxygen, nitrogen, sulfur and phosphorous is present, can be defined as inorganic compound.
On the basis of the previous considerations, many research groups are focused on the synthesis and development of new metal-based chemotherapeutics with a wide scope of applicability. Few know that for this kind of compounds the in silico evaluations are not always reliable. Therefore, a "tailored" design must consider each component of the final chemical structure, starting from the metal choice, the available oxidation states up to the desired ligands coordination sphere. This cognitive process requires deep knowledge of bioinorganic chemistry and interdisciplinary capabilities. Organic and "biological" drugs can be designed as species able to bind various biomolecules within specific pockets or surfaces with topological (e.g., molecular shape and electronic charge distribution) complementarity. On the contrary, the inherent nature of inorganic species allows a multi-target approach in treating various diseases, mainly malignancies. For this reason, it is often possible to elucidate their mechanism of action at the molecular level only a posteriori, finding out that more than one intracellular target and pathway are affected by the metal-based compounds. This behavior can be exploited to overcome the intrinsic or acquired resistance of tumors toward clinically used drugs, also in combination therapies. At the best of our knowledge, only gold compounds already recognized by FDA (US) for the treatments of reumatoid arthritis (Myocrisin and Auranofin) are now in clinical trials (phase I and II) for cancer treatments [31, 32] .
In the light of the close analysis of the 21 patents here summarized, it leaps out that the majority of the inventions focuses on in vitro studies which are not sufficient to state the effectiveness of the potential drugs in terms of antiproliferative or anti-flogistic activity. In fact, only the in vivo tests could really assess the innovative and promising nature of the compounds. Some patents are actually interesting with good inhibitory effects in animal models. Moreover, a few inventions or related papers report on toxicity data as well, showing negligible or absent sideeffects for the patented gold derivatives, endowed with a very encouraging chemotherapeutic index in terms of toxicity/efficacy ratio. Thus, future in vivo tests will be of paramount importance in discriminating among the different classes of gold compounds and hence, to understand which are really ground-breaking, thus leading the big Pharma Companies to address their interests to this market niche.
While reading carefully every patent, some weaknesses become evident for a few of them. For instance, the preparations and the physico-chemical characterizations of the different compounds are not always clearly described. Moreover, in the biological in vitro studies, the vehicle is not always stated along with the solution stability of the complexes over time. This is a very important issue as metalbased derivatives are often unstable in solution due to ligand exchange or redox processes. In particular, PBS is often exploited as a medium but it has to be considered that the phosphate group is a good potential ligand for gold ions and it may substitute one or more ligands. Likewise, the time of incubation and the number of seeded cells are not always reported and, remarkably, the compound concentrations are sometimes expressed as mg/mL instead of μM, thus preventing a fast and proper comparison of the data coming from different research groups. Another point to be underlined is related to the use of cisplatin as a reference drug. Despite its appropriateness, some researchers predissolve it in DMSO before the treatments, thus decreasing its activity upon solvent coordination and, hence, distorting the comparative values. In our opinion, saline solution should be used (solubility < 4 mM) to detect cisplatin actual efficacy. Furthermore, we suggest to carry out the in vitro tests by several independent experiments under at least quadruplicate conditions and to standardize the incubation time to 72 h, required by cisplatin to achieve its antitumor activity.
Concerning the different possible mechanisms of action identified for the patented compounds, we can list the inhibition of aquoglyceroporins (AQPs) [90] , the selenoenzyme thioredoxin reductase (TrxR) [113, 116] , the proteasome [116] , class I histone deacetylase (HDAC) [113, 114] and the angiogenesis process [62] . In particular, it should be highlighted that the anti-angiogenic therapy [138] , which aims to destroy the tumor by shutting down its blood supply, may instead stimulate cancer cells to disseminate in other districts (metastasis), in search for a more oxygenated milieu [139] . In fact, tumor hypoxia is associated with enhanced malignancy and invasiveness, by promoting transcriptional activation of the c-met proto-oncogene followed by a cascade of invasive growth program [140] .
In the light of the identified targets, the related patented complexes to stand out for innovation with a great translational potential. Regarding the AQP-targeting potential drugs, the results collected in one invention could pave the way to the treatment of several diseases besides cancer, such as obesity, kidney impairment, glaucoma, brain edema and epilepsy [90, 92] . With respect to the multicatalytic protease proteasome, one patent is in the field of the modern targeted anticancer therapies. In fact, the corresponding derivatives are designed to be recognized by the peptide transporters (PEPTs) on the cell membrane. In the light of the collected results, PEPTs represent an excellent target for the selective delivery of pharmacologically active compounds [116] .
In many cases, it is likely that the gold compounds behave as "prodrugs", namely they require a "chemical activation" process. For some patented compounds, also the corresponding ligands were properly tested and proved inactive. Thus, it results that the coordinated metal is essential in fulfilling the activity. In this context, as mentioned in the section 1.3, the chemical features of gold differ a lot from the other elements of the periodic table. In particular, its oxidation states +1 and +3 can be exploited to elicit biological effects when stabilized against reduction by proper ligands. On the other hand, gold offers the advantage of becoming an inert non-toxic species (Au 0 ) after accomplishing its anticancer or anti-inflammatory "mission".
In conclusion, in the field of gold derivatives for medicinal applications, the ultimate goal is to broaden the therapeutic spectrum of current drugs, namely to find out strategies able to cure patients with diseases resistant to various clinically-established drugs. In addition, the compounds with a good toxicological profile could be beneficial in treating patients at a lower dosage if compared to drugs already in clinical use, avoiding the onset of severe side effects. Finally, in the oncology field, these may represent the only cure for some "orphan" tumors, including the triple negative breast cancer.
CONCLUDING REMARKS
This contribution covers lately published patents whose gold(I,III) compounds are claimed as potential anticancer and/or anti-inflammatory drugs. In particular, we have described 21 national and international inventions related to both coordination and organogold derivatives. In the introduction a wide scenario of possibilities involving metalbased compounds has been mentioned, starting from the socalled "cold" metals up to the "hot" ones, being exploitable as pivotal moieties in various agents for treating or diagnosing several diseases. The dissertation, here divided into two sections for the different classes of gold(I) and gold(III) compounds, highlights the great deal of potential of this metal with peculiar chemical properties, able to undergo
